# UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

IN RE KALOBIOS PHARMACEUTICALS, INC. SECURITIES LITIGATION

THIS DOCUMENT RELATES TO ALL ACTIONS

Case No. 5:15-cv-05841-EJD

**CLASS ACTION** 

#### PROOF OF CLAIM AND RELEASE FORM

### A. GENERAL INSTRUCTIONS & INFORMATION

- 1. You are urged to read carefully the accompanying Notice of Proposed Settlement of Class Action, Motion for Attorneys' Fees and Expenses, and Settlement Fairness Hearing (the "Notice"). All capitalized terms used herein shall have the same meaning as defined in the Notice.
- 2. If you have already submitted a valid and timely Proof of Claim and Release Form ("Proof of Claim") for the prior Partial Settlement in this Action with former Defendants KaloBios, Ronald Martell, and Herb Cross, you need not submit this form and your previous Proof of Claim will be used. If you have not previously submitted a valid and timely Proof of Claim in this Action, and you wish to file a claim and recover under the Settlement of this Action, you must submit this Proof of Claim. However, filing a Proof of Claim is not a guarantee that you will share in the proceeds of the Settlement in the Action.
- 3. You must mail your completed and signed Proof Of Claim postmarked on or before June 18, 2018, addressed to the Settlement Administrator at:

KaloBios Pharmaceuticals, Inc. Securities Litigation

c/o Strategic Claims Services 600 North Jackson Street, Suite 205 Media, PA 19063

> Tel: 866-274-4004 Fax: 610-566-7985

Email: info@strategicclaims.net

- 4. If you are a member of the Settlement Class and you do not timely request exclusion, you will be bound by the terms of any judgment entered in the Action.
  - 5. If you are **not** a member of the Settlement Class, **do not** submit a Proof of Claim.
  - 6. For help completing this Proof of Claim, please contact the Settlement Administrator.

## B. INSTRUCTIONS FOR FILLING OUT THE PROOF OF CLAIM FORM

Important additional information regarding the Settlement and this Proof of Claim is contained in the Notice posted on the Settlement Administrator's website, www.strategicclaims.net/kalobios. Please refer to the Plan of Allocation set forth in the Notice for a detailed explanation of how a Claimant's Recognized Loss will be calculated.

- 1. In order to be eligible to participate in the distribution of the Net Settlement Fund, a claimant ("Claimant") must have purchased or otherwise acquired KaloBios Pharmaceuticals, Inc. ("KaloBios") common stock during the period between November 19, 2015 and December 16, 2015, inclusive (the "Settlement Class Period").
- 2. The submission of a Proof of Claim does not ensure that your claim will be upheld or that you will share in any recovery. All claims are subject to verification and investigation. You may be requested to provide further information.
- 3. All claims must be made by persons or entities who were beneficial owners (as opposed to record holders or nominees) of shares of KaloBios common stock. (Brokerage firms, banks and other nominees are requested to transmit copies of the Notice and Proof of Claim to their present or former customers who were such beneficial owners.) If shares of KaloBios common stock were owned jointly, all joint owners must complete and sign the Proof of Claim.
- 4. Executors, administrators, guardians, conservators and trustees may complete and sign the Proof of Claim on behalf of persons or entities represented by them, but they must identify such persons or entities and provide proof of their authority (*e.g.*, powers of attorney or currently effective letters testamentary or letters of administration) to do so.
- 5. You must file a separate Proof of Claim for each differently named account or ownership, such as an individual account, an IRA account, a joint account, or a custodial account, etc. Joint tenants, co-owners, or custodians UGMA should file a single claim. Claimants who file one or more claims (*e.g.*, one in Claimant's name and one for an IRA or joint ownership) must identify the other claims filed.
- 6. The date of purchase and/or sale of shares of KaloBios common stock is the "trade" date and not the "settlement" date.
  - 7. The first-in, first-out basis ("FIFO") will be applied to both purchases and sales.
- 8. Exercise of option contracts will be considered to be purchases or sales of common stock. Option premiums will be incorporated into the purchase/sale price of the common stock accordingly.
- 9. The date of covering a "short sale" is deemed to be the date of purchase of KaloBios common stock; and the date of a "share sale" is deemed to be the date of sale of KaloBios common stock. Shares originally sold short will have a Recognized Loss of zero.
- 10. No cash payment will be made on a claim where the potential distribution is less than ten dollars (\$10.00).
- 11. You must attach to your claim form **copies** of brokerage confirmations, monthly statements or other documentation of your transactions in KaloBios common stock in order for your claim to be valid. If such documents are not available, a complete list of acceptable supporting documentation can be found on the Settlement Administrator's website: www.strategicclaims.net (click on "Cases" and then click on "KaloBios Pharmaceuticals, Inc. Securities Litigation"). Failure to provide this documentation could delay verification of your claim or could result in rejection of your claim.
- 12. If your trading activity during the Settlement Class Period exceeds 50 transactions, you must provide all purchase and sale information required in the Schedule of Transactions in an electronic file. For a copy of instructions and the parameters concerning an electronic submission, contact the Settlement Administrator by phone: 866-274-4004; or via the website: www.strategicclaims.net.
- 14. If you have questions or need additional Proofs of Claim, contact the Settlement Administrator via the information in the preceding paragraph. You may make photocopies of this form.

# **PROOF OF CLAIM**

The Settlement Administrator must receive this form postmarked no later than June 18, 2018.

# C. CLAIMANT IDENTIFICATION (Please Type or Print)

Beneficial Own	er's Name (as it appears on yo	ur brokerage statement)		
Joint Beneficial	Owner's Name (as it appears	on your brokerage statemen	(t)	
Street Address				
City		State	Zip Code	
Foreign Province / Country		Social Security or Taxpayer Identification Number		
Specify one of	the following:			
Individual(s)	Corporation	UGMA Custodian	IRA	
Partnership	Estate	Trust	Other:	
		(Day)		(Evening)
Area Code	Telephone Number	Area Code	Telephone Number	
Facsimile Number		E-Mail Address		
Record Owner's	s Name and Address (if differen	nt from beneficial owner list	ed above)	

# D. SCHEDULE OF TRANSACTIONS IN KALOBIOS COMMON STOCK

	• -	chase of KaloBios common states of KaloBios	
Purchase Date (list chronologically) Month/Day/Year	Number of Shares Purchased	Price Per Share (excluding commissions, taxes, and other fees)	Total Purchase Price (excluding commissions, taxes, and other fees)
//		\$	\$
//		\$	\$
//		\$	\$
/ /		\$	\$
documented):  Sale Date (list chronologically)	Number of Shares Sold	Price Per Share (excluding commissions,	Total Sale Price (excluding commissions,
documented):  Sale Date	Number of	Price Per Share	Total Sale Price
documented):  Sale Date (list chronologically)	Number of	Price Per Share (excluding commissions, taxes, and other fees)	Total Sale Price (excluding commissions, taxes, and other fees)
documented):  Sale Date (list chronologically)	Number of	Price Per Share (excluding commissions, taxes, and other fees)	Total Sale Price (excluding commissions, taxes, and other fees)
documented):  Sale Date (list chronologically)	Number of	Price Per Share (excluding commissions, taxes, and other fees) \$	Total Sale Price (excluding commissions, taxes, and other fees) \$
Sale Date (list chronologically) Month/Day/Year //	Number of Shares Sold  er of shares of and at the close	Price Per Share (excluding commissions, taxes, and other fees)  \$ \$ \$  KaloBios common stock owese of trading on January 13,	Total Sale Price (excluding commissions, taxes, and other fees)  \$ \$ \$ with the close of trading
Sale Date (list chronologically) Month/Day/Year /	Number of Shares Sold  er of shares of and at the clost than zero, must	Price Per Share (excluding commissions, taxes, and other fees)  \$ \$ \$  KaloBios common stock owese of trading on January 13,	Total Sale Price (excluding commissions, taxes, and other fees)  \$ \$ \$  with the close of trading the company of the close of trading the company of the company of the close of trading the company of the close of trading the company of the close of trading the

1. State the total number of shares of KaloBios common stock owned at the close of trading on

YOU MUST ALSO READ THE RELEASE AND SIGN THE CERTIFICATION OR THE W-8 CERTIFICATION BELOW

#### E. SUBMISSION TO JURISDICTION OF THE COURT

By submitting this Proof of Claim Form and Release, I/we, and every Settlement Class Member I/we represent, submit to the jurisdiction of the United States District Court for the Northern District of California for purposes of this Action and the Settlement of the Action, as reflected in the Stipulation of Settlement (the "Stipulation"). I/We further agree to be bound by the orders of the Court, agree that this Proof of Claim Form, my/our status or the status of the Settlement Class Member I/we represent as a Claimant, and the allowable amount of this claim will be subject to review and further inquiry, and that I/we will furnish such additional documentation with respect to this Proof of Claim as may be required.

#### F. RELEASE

- 1. By signing this Proof of Claim Form and Release, and in consideration of the establishment of the Settlement Consideration, as of the effective date thereof, the undersigned claimant ("Claimant") hereby releases and forever discharges (a) Settling Defendant Martin Shkreli; (b) Shkreli's immediate family members, his successors and assigns, and his insurers (altogether the "Released Parties"), from any and all claims, both known and Unknown Claims, alleged or which could have been alleged or pled or which could have been pled in the Action against the Settling Defendant or any of the Released Parties, for any alleged injury to a Settlement Class Member arising from the facts and circumstances at issue in the Action or related in any way to Shkreli's tenure at KaloBios, alleged misstatements or omissions made by Shkreli, and transactions by any Settlement Class Member in KaloBios stock, whether known or Unknown Claims, whether direct or for indemnification, contribution or otherwise, and whether arising under state, federal, or common law, and including any claim for recovery of liability to the Settlement Class or its members for any costs, expenses or attorneys' fees, but excepting claims to enforce this Settlement (the "Settlement Class Claims").
- 2. Conversely, the Settling Defendant hereby releases and forever discharges any and all actual and potential claims, counterclaims, and bases for relief, whether known or Unknown Claims, that the Settling Defendant could have raised in the Action against the Plaintiffs or Lead Counsel including but not limited to claims arising under Fed. R. Civ. P. 11 or any other claims seeking reimbursement of costs, expenses, or attorneys' fees, but excepting claims to enforce this Settlement. (the "Defendant Claims").
- 3. For purposes of these release provisions, "Unknown Claims" means (i) any and all Settlement Class Claims that a Claimant does not know or suspect to exist in his, her, or its favor at the time of the release of the Released Parties and the Settling Defendant, which if known by him, her, or it might have affected his, her, or its decision(s) with respect to the Settlement; and (ii) and any and all Defendant Claims that the Settling Defendant does not know or suspect to exist in his favor, which if known by him might have affected his decision(s) with respect to the Settlement. With respect to the Settled Claims, the Settling Parties stipulate and agree that upon the Effective Date, the Plaintiffs and the Settling Defendant shall expressly waive, and each Settlement Class Member shall be deemed to have waived, and by operation of the Judgment shall have expressly waived any and all provisions, rights and benefits conferred by any law of any state or territory of the United States or principle of common law, that is similar, comparable, or equivalent to Cal. Civ. Code § 1542, which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

The Settling Parties acknowledge, and Settlement Class Members by operation of law shall be deemed to have acknowledged, that the inclusion of "Unknown Claims" in the definition of Settlement Class Claims and Defendant Claims was separately bargained for and was a key element of the Settlement.

#### **G. REPRESENTATIONS**

I/We acknowledge that I/we have read the Notice of Proposed Settlement of Class Action, Motion for Attorneys' Fees and Expenses, and Settlement Fairness Hearing, and that pursuant thereto I/we file this claim to participate in the Settlement.

I/We hereby warrant and represent that neither I/we, nor any person I/we represent, is a Defendant (as defined in the Notice) with respect to any of the claims asserted in the Litigation, a member of the immediate family of any of the Defendants, or anyone excluded from the Settlement Class as it is defined in the Stipulation, or a person or entity who has requested exclusion from the Class.

I/We hereby warrant and represent that I am/we are authorized to execute and deliver this Proof of Claim Form and Release.

## **H. CERTIFICATION**

I/We certify that I am/we are not subject to backup withholding. (If you have been notified by the IRS that you are subject to backup withholding, strike out the previous sentence.).

I/We certify that I/we purchased or otherwise acquired the KaloBios common stock listed in the above Schedule during the period between November 19, 2015 and December 16, 2015, inclusive.

Claim was executed this	day of	, 2018 in:
(City)	(State/Country)	
Signature of Claimant		Signature of Joint Claimant, if any
(Print your name here)		(Print your name here)
Signature of Person signing Claimant	on behalf of	
(Print your name here)		
(Print your name here)  Capacity of person signing Claimant, if other than (Executor, President, Custodia	an individual,	

# **SUBSTITUTE FORM W-8:** IF YOU ARE NOT A RESIDENT OR CITIZEN OF THE UNITED STATES, COMPLETE THE FOLLOWING:

Permanent residence (principal office if a corporation)

If your claim is connected with a trade or business conducted in the U.S., please provide the name and address of your U.S. business, the type of business, and the Federal Tax Identification Number of the U.S. business.

Name of U.S. Business	
Address of U.S. Business	
Type of Business	Tax Identification Number
W-8 Certification: Under the pen correct and complete.	alties of perjury, I certify that the information provided above is true,
Signature(s)	Date:
	Date:

# ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME. THANK YOU FOR YOUR PATIENCE.

#### **Reminder Checklist:**

- 1. Remember to sign the above Release and Certification (or W-8 Certification).
- 2. Remember to attach only **copies** of acceptable supporting documentation, a complete list of which can be found on the Claims Administrator's website at www.strategicclaims.net.
- 3. Do not send originals of securities certificates.
- 4. Keep copies of the completed claim form and documentation for your own records.
- 5. If you desire an acknowledgment of receipt of your claim form, please send it Certified Mail, Return Receipt Requested, or its equivalent. You will bear all risks of delay or non-delivery of your claim.
- 6. If your address changes in the future, or if these documents were sent to an old or incorrect address, please send us **written** notification of your new address.

If you have questions or concerns regarding your claim, please contact the Claims Administrator at:

KaloBios Pharmaceuticals, Inc. Securities Litigation c/o Strategic Claims Services 600 North Jackson Street, Suite 3 Media, PA 19063 Tel: 866-274-4004 Fax: 610-565-7985

Fax: 610-565-7985 info@strategicclaims.net

KaloBios Pharmaceuticals, Inc. Securities Litigation c/o Strategic Claims Services 600 North Jackson Street, Suite 205 Media, PA 19063

# IMPORTANT LEGAL DOCUMENT – PLEASE FORWARD